Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Understand why the SP 500 garners so much attention from investors. A brief look at liquidity, breadth, and what movers it signals.
20,952 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A timely wealth story shows how Naomi Osaka's boundary-first approach translates into smart money moves for 2026, urg...
Peloton has faced a brutal selloff, but the story isn’t finished. This article dives into whether Peloton is broken o...
A growing number of employers are layering cash balance features into 401(K) plans, allowing large annual deferrals f...
Betterware de Mexico appears to be trading at a discount despite a growth plan centered on Latin America expansion an...
SpaceX finally opened its doors to public markets, signaling a pivotal moment for growth investors. This guide breaks...
If SpaceX ever files for an IPO, the prospectus would reveal the core drivers, the risks, and the questions investors...
AI verification flags a missing proof in a landmark 1976 economic theorem, risking a rethink of models relied upon in...
Broadcom posted a solid quarter but guided toward softer AI chip sales, sending its stock lower and dragging peers li...
Beyond Meat is shifting from plant-based meat to protein drinks. This article explores whether beyond meat's pivot pr...
A surprising rally in small-cap value equities challenges the usual price-pressures from inflation and higher rates. ...
Planet Labs sinks 10% in early trading as traders rotate capital toward SpaceX-linked opportunities, signaling a sect...